OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Clinical Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.	1025
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.	951
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.	712
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.	702
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.	648
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.	613
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.	604
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.	576
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non–small-cell lung cancer (NSCLC) refractory to first-line o	545
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.	536
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.	485
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.	479
Representativeness of patients with lung cancer in an integrated health care delivery system.	460
The molecular signature of gain-of-function (GOF) vs. non-GOF classification TP53 mutations in colorectal cancer.	448
Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.	432
Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.	407
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.	401
Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.	381
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).	366
Early integration of exercise into breast cancer care: The MSK healthy living program.	363
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.	362
Impact of economic inequality on Kaposi sarcoma of the lung: A retrospective cohort.	356
Information and decisional needs of patients (pts) with newly diagnosed advanced cancer in the hospital: A multi-level, mixed-methods study.	351
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.	345
Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.	343

Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.	339
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.	331
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.	328
Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.	322
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).	310
Multi-omics study of the genomic features and clinical characteristics of hepatic sarcomatoid carcinoma located at different sites.	307
Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma.	299
Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions.	298
Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.	285
Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?	284
Enhancing patient clinical streamlining (EPACS) pilot in the breast medicine service at memorial sloan kettering cancer center.	283
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patie	276
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NS	273
Hearing loss related outcomes post-lateral temporal bone resection and other oncologic treatment.	267
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controll	267
Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.	265
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.	258
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.	250
The impact of using Elsevier ClinicalPath oncology treatment pathways on survival and cost of care.	249
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.	246
Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.	242
Predicting therapy-induced cardiomyopathy in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).	241
A national survey of current scenario and future perspectives of cancer research in Brazil.	240
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).	239
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.	239
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.	232
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.	231
Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.	229
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).	228
The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis.	228
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.	228
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.	225
Ten-year outcomes of hypofractionated (45 Gy in 9 fractions) intensity-modulated radiotherapy for localized prostate cancer.	224
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.	224
A Lasso Cox score consisting of CTLA4⁺ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3⁺ CD8⁺ T cells: Association with adjuva	221
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx stud	220
Surgery with adjuvant chemotherapy versus chemoradiation for early-stage large cell neuroendocrine cancer (LCNEC) of the lung: A SEER plus based analysis.	220
Subsequent meningiomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).	219
3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors.	218
Positive margin and advanced depth of invasion as the indicators for assessing the necessity of adjuvant chemoradiotherapy in early-stage oral cavity squamous cell carcinoma.	216
Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.	215
ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer.	215
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.	214
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.	214
A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.	213
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.	206
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).	203
Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.	203
Clinical and molecular Characterization of NSCLCs with MET exon 14 skipping mutation coexist MET amplification.	202
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.	199

Racial and income characteristics and the burden of illness among metastatic prostate cancer patients.	197
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.	196
Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.	191
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.	189
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.	186
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.	182
The Ohio State University Guardant Shield Colorectal Cancer Screening Project.	181
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.	181
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II	181
Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis.	176
A national analysis evaluating the role of neoadjuvant chemoradiotherapy in upper esophageal cancer.	176
Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC).	176
Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal ca	175
Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A r	173
Artificial neural network model analysis in T790M detection after failure of first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.	172
The impact of COVID-19 on anxiety among breast cancer survivors before, during and after the pandemic.	171
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.	170
Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.	169
Relationship between androgen biosynthesis linked to 3βHSD1 and resistance to radiotherapy: A germline biomarker for combined androgen blockade with radiation in high-risk prostate cancer.	168
Patterns of diversity in cancer clinical trial enrollment at a New York City academic health system, 2018-2022.	167
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.	167
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.	165
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).	164
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.	164
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.	162
Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.	162
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.	161
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.	161
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.	160
Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network.	159
Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study.	159
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.	158
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.	157
Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.	154
Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperabl	153
Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.	153
The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients.	152
Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.	152
Scenery of multilocus inherited neoplasia alleles syndrome (MINAS) in a single Brazilian institution.	152
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.	152
Mutational profiles of sporadic synchronous colorectal cancer.	151
Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.	151
A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regi	151
Pan-Cancer analysis of the mutation frequency of genes in DDR pathway in Chinese population.	151
Improving goal concordant care clinician workshops: Do patients benefit?	149
A cross sectional study on female sexual function following pelvic radiotherapy.	149
Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.	147
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.	147
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).	147
Hereditary cancer screening at an urban safety net hospital.	147
Participation in cancer research in BNSSG, England: A Health Equity Audit 2021.	146
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.	145
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.	144
Gene expression correlates of adagrasib response in KRAS^G12C mutated non-small cell lung cancer (NSCLC).	144
Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.	144
Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.	143
The relationship of oncotype Dx Recurrence Score (RS) with Ki 67 in early stage breast cancer patients in a community based cancer center in rural central Nebraska.	142
Is recent FDA guidance on HRQoL clinical significance a barrier to clinician/patient treatment risk/benefit discussions: An example using EORTC scale endpoints in a randomized, phase 3 trial.	139
Race- and sex-based variation in industry research and general payments to medical oncologists in the United States.	138
CD47 expression patterns in thymic epithelial tumors.	136
Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.	136
Financial distress, health literacy, numeracy, and treatment receipt by race/ethnicity amongst breast cancer survivors.	135
Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy.	135
Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.	135
Genomic landscape and clonal evolution between adenocarcinoma and squamous components in adenosquamous carcinoma of the pancreas.	132
Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites.	130
Systematic assessment of online health information related to drug therapy for non-small cell lung cancer.	130
Awareness of the link between HPV, cervical cancer, and HPV vaccination: An online survey among Polish women.	129
Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.	129
Patients with cancer symptom and physical function reporting by caregivers as predictors of adverse clinical outcomes.	129
Variation in survival rates among patients with angiosarcoma based on demographic and socioeconomic factors in academic versus non-academic settings: An NCDB analysis.	129
Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.	128
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.	127
The prognostic role of sarcopenia and albumin in locally advanced renal cell carcinoma with IVC tumor thrombus.	127
Trends in the incidence of early-onset invasive colorectal cancer between 1990 and 2018, stratified by race/ethnicity, gender, and anatomic sub-sites among Pennsylvania residents.	127
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.	127
Adult BMI change over time and risk of colorectal adenoma.	126
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).	126
Quality of educational YouTube videos related to pancreatic cancer: Analysis of patient-focused and NCI-designated cancer center videos.	125
A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection.	125

Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.	125
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.	123
Tumour radiomics as imaging biomarker of tumour response to chemo-radiotherapy in patients with adenocarcinoma of rectum.	123
Correlation between PD-L1 high-expression and EGFR variants in non-small cell lung cancer.	122
Risk of second cancers in long term survivors of neuroendocrine tumors of the large intestine.	122
Factors associated with weekend emergency department visits in patients with GI cancer.	122
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.	120
Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.	120
Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic c	120
Anlotinib combined with induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase II study.	119
Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.	118
Dysregulated Th1 cells in lung squamous cell carcinoma.	118
Early patient-reported outcomes are a promising predictive factor of cancer progress and outcome in older patients: The EPROFECY study.	118
Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).	118
Tyrosine kinase inhibitors (TKIs) in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study.	117
A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.	117
Baseline endogenous corticosteroid as a biomarker for predicting response to immune checkpoint blockade in patients with metastatic cancer.	117
A novel approach to assessing the effects of smoking on treatment response rate in muscle-invasive bladder cancer.	116
The impact of COVID-19 infection on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.	115
Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.	114
Using variant allelic fraction of driver mutations to determine the reliability of MGMT promoter methylation testing in adult-type diffuse gliomas.	113
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.	113
Demographic and laboratory determinants of humoral immune responses and impact of different anti-SARS-CoV-2 vaccine platforms in patients with cancer: A systematic review and meta-analysis.	113
Significance of induction chemotherapy combined with cetuximab in laryngeal preservation rate of locally advanced hypopharyngeal cancer.	112
Using nucleosome levels, copy number alterations, and DNA methylation to profile disease state through liquid biopsy.	112
Real-world effectiveness of anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer.	112
Identifying mechanisms of acquired immune escape from sequential, paired biopsies.	112
Pan-cancer analysis of BRAF alterations and tumor-specific mechanisms of activation.	111
Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT).	111
The role of RARRES2 in regulating lipic metabolic reprogramming in the development of brain metastases in triple negative breast cancer.	110
Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression.	110
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis	110
Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.	109
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.	109
Multimodal approach to capture spatially resolved single-cell tumor heterogeneity in breast cancer.	109
Total and anatomically contextualized quantitative ¹⁸F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.	108
Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.	108
Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.	108
Racial disparities in genitourinary cancer mortality trends in the United States, 2000-2020: A CDC database study.	107
Secondary primary malignancies among patients with GU cancer.	106
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).	106
Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the ph	105
Patterns of early 18F-FDG PET response to nivolumab (NIVO) and ipilimumab nivolumab (IPINIVO) in patients with metastatic renal cancer (MRC).	104
Role of thromboprophylaxis during neoadjuvant chemotherapy before radical cystectomy in patients with bladder cancer: Results of a multicenter retrospective cohort study.	104
Key parameters that influence surgical strategy in localised kidney cancer.	104
Improving health education through a patient-clinician partnered intervention in the patient with genitourinary cancer.	104
Multi-dimensional measurements of long-term quality of life and recovery patterns of patients with cervical cancer after treatment.	103
First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.	103
Short-term and long-term outcomes of transduodenal ampullectomy for patients with early ampullary cancer.	103
Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.	102
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as first-line treatment for unresectable intrahepatic cholangiocarcinoma: A propensity score matched analysis.	102
Performance of the F-PSMA 1007 PET/CT for high-risk prostate cancer staging: Experience from a Latin American reference center.	102
Targeting exercise and sedentary behavior for the prevention of allogeneic stem cell transplant-related cardiovascular dysfunction: The ALLO-Active trial.	101
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).	100
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.	100
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.	100
Analyzing the effect of treatment modalities on survival in synovial sarcoma.	99
Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit.	99
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.	98
Association of enhanced epithelial-mesenchymal transition signature with tumor microenvironment, angiogenesis, and survival in gastric cancer.	97
Identifying DNA methylation signatures in high-grade serous ovarian cancer: Results vary by control tissue type.	97
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.	97
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).	97
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.	95
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou	95
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.	95
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect	94
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617) use by US urologists and oncologists.	94
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.	93
Liver steatosis and fibrosis as independent prognostic factors affecting survival in colorectal cancer with liver metastases.	93
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.	93
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.	93
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology	92
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.	92
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.	91
Ground-glass opacity showed response to immunotherapy in cancer patients.	90
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.	90
The role of exosomal LINC00853 in gastric cancer progression.	90
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.	90
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?	90
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.	90
Assessing disparities in pancreatic cancer outcomes in African Americans.	90
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.	89
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.	89
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.	89
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom	88
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.	88
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.	88
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.	88
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.	87
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.	87
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.	87
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.	86
Genomic instability is enriched in localized prostate cancers from men of African ancestry.	86
Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.	86